Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
17 10 2023
17 10 2023
Historique:
received:
24
01
2023
accepted:
14
06
2023
medline:
23
10
2023
pubmed:
22
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
Cadaveric studies have shown disease-related neurodegeneration and other morphological abnormalities in the retina of individuals with Parkinson disease (PD); however, it remains unclear whether this can be reliably detected with in vivo imaging. We investigated inner retinal anatomy, measured using optical coherence tomography (OCT), in prevalent PD and subsequently assessed the association of these markers with the development of PD using a prospective research cohort. This cross-sectional analysis used data from 2 studies. For the detection of retinal markers in prevalent PD, we used data from AlzEye, a retrospective cohort of 154,830 patients aged 40 years and older attending secondary care ophthalmic hospitals in London, United Kingdom, between 2008 and 2018. For the evaluation of retinal markers in incident PD, we used data from UK Biobank, a prospective population-based cohort where 67,311 volunteers aged 40-69 years were recruited between 2006 and 2010 and underwent retinal imaging. Macular retinal nerve fiber layer (mRNFL), ganglion cell-inner plexiform layer (GCIPL), and inner nuclear layer (INL) thicknesses were extracted from fovea-centered OCT. Linear mixed-effects models were fitted to examine the association between prevalent PD and retinal thicknesses. Hazard ratios for the association between time to PD diagnosis and retinal thicknesses were estimated using frailty models. Within the AlzEye cohort, there were 700 individuals with prevalent PD and 105,770 controls (mean age 65.5 ± 13.5 years, 51.7% female). Individuals with prevalent PD had thinner GCIPL (-2.12 μm, 95% CI -3.17 to -1.07, Individuals with PD have reduced thickness of the INL and GCIPL of the retina. Involvement of these layers several years before clinical presentation highlight a potential role for retinal imaging for at-risk stratification of PD.
Sections du résumé
BACKGROUND AND OBJECTIVES
Cadaveric studies have shown disease-related neurodegeneration and other morphological abnormalities in the retina of individuals with Parkinson disease (PD); however, it remains unclear whether this can be reliably detected with in vivo imaging. We investigated inner retinal anatomy, measured using optical coherence tomography (OCT), in prevalent PD and subsequently assessed the association of these markers with the development of PD using a prospective research cohort.
METHODS
This cross-sectional analysis used data from 2 studies. For the detection of retinal markers in prevalent PD, we used data from AlzEye, a retrospective cohort of 154,830 patients aged 40 years and older attending secondary care ophthalmic hospitals in London, United Kingdom, between 2008 and 2018. For the evaluation of retinal markers in incident PD, we used data from UK Biobank, a prospective population-based cohort where 67,311 volunteers aged 40-69 years were recruited between 2006 and 2010 and underwent retinal imaging. Macular retinal nerve fiber layer (mRNFL), ganglion cell-inner plexiform layer (GCIPL), and inner nuclear layer (INL) thicknesses were extracted from fovea-centered OCT. Linear mixed-effects models were fitted to examine the association between prevalent PD and retinal thicknesses. Hazard ratios for the association between time to PD diagnosis and retinal thicknesses were estimated using frailty models.
RESULTS
Within the AlzEye cohort, there were 700 individuals with prevalent PD and 105,770 controls (mean age 65.5 ± 13.5 years, 51.7% female). Individuals with prevalent PD had thinner GCIPL (-2.12 μm, 95% CI -3.17 to -1.07,
DISCUSSION
Individuals with PD have reduced thickness of the INL and GCIPL of the retina. Involvement of these layers several years before clinical presentation highlight a potential role for retinal imaging for at-risk stratification of PD.
Identifiants
pubmed: 37604659
pii: WNL.0000000000207727
doi: 10.1212/WNL.0000000000207727
pmc: PMC10585674
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1581-e1593Subventions
Organisme : Medical Research Council
ID : MR/TR000953/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T040912/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T019050/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205167/Z/16/Z
Pays : United Kingdom
Investigateurs
Naomi Allen
(N)
Tariq Aslam
(T)
Denize Atan
(D)
Sarah Barman
(S)
Jenny H Barrett
(JH)
Paul Bishop
(P)
Graeme Black
(G)
Tasanee Braithwaite
(T)
Roxana O Carare
(RO)
Usha Chakravarthy
(U)
Michelle Chan
(M)
Sharon Yl Chua
(SY)
Alexander Day
(A)
Parul Desai
(P)
Bal Dhillon
(B)
Andrew D Dick
(AD)
Alexander Doney
(A)
Cathy Egan
(C)
Sarah Ennis
(S)
Marcus Fruttiger
(M)
John Ej Gallacher
(JE)
David F Garway-Heath
(DF)
Jane Gibson
(J)
Jeremy A Guggeinheim
(JA)
Chris J Hammond
(CJ)
Alison Hardcastle
(A)
Simon P Harding
(SP)
Ruth E Hogg
(RE)
Pirro Hysi
(P)
Sir Peng T Khaw
(S)
Gerassimos Lascaratos
(G)
Thomas Littlejohns
(T)
Andrew J Lotery
(AJ)
Robert Luben
(R)
Phil Luthert
(P)
Tom Macgillivray
(T)
Sarah Mackie
(S)
Bernadette McGuiness
(B)
Gareth J McKay
(GJ)
Marin McKibbin
(M)
Tony Moore
(T)
James E Morgan
(JE)
Eoin O'Sullivan
(E)
Richard Oram
(R)
Chris G Owen
(CG)
Euan Paterson
(E)
Tunde Peto
(T)
Alicja R Rudnicka
(AR)
Naveed Sattar
(N)
Jay Self
(J)
Panagiotis Sergouniotis
(P)
Sobha Sivaprasad
(S)
David Steel
(D)
Irene Stratton
(I)
Nicholas Strouthidis
(N)
Cathie Sudlow
(C)
Zihan Sun
(Z)
Robyn Tapp
(R)
Dhanes Thomas
(D)
Emanuele Trucco
(E)
Adnan Tufail
(A)
Veronique Vitart
(V)
Ananth C Viswanathan
(AC)
Mike Weedon
(M)
Cathy Williams
(C)
Katie Williams
(K)
Jayne V Woodside
(JV)
MaxM Yates
(M)
Jennifer Yip
(J)
Yalin Zheng
(Y)
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Ann Neurol. 2020 Nov;88(5):893-906
pubmed: 32881029
J Comp Neurol. 1990 Nov 15;301(3):461-89
pubmed: 1979792
JAMA Neurol. 2018 Oct 1;75(10):1256-1263
pubmed: 29946702
BMC Med Res Methodol. 2020 Jun 8;20(1):148
pubmed: 32513107
Neurology. 2018 Sep 11;91(11):e1003-e1012
pubmed: 30111550
Brain. 2021 Nov 29;144(10):3114-3125
pubmed: 33978742
Brain. 1996 Apr;119 ( Pt 2):585-91
pubmed: 8800950
J Neural Transm (Vienna). 2019 Dec;126(12):1695-1699
pubmed: 31630254
Lancet Neurol. 2017 Oct;16(10):797-812
pubmed: 28920886
Mov Disord. 2020 Mar;35(3):478-485
pubmed: 31846123
PLoS One. 2012;7(4):e34891
pubmed: 22514688
Ophthalmology. 2019 Apr;126(4):497-510
pubmed: 30114417
J Neural Transm (Vienna). 2014 Jan;121(1):41-7
pubmed: 23907408
Mov Disord. 2020 Feb;35(2):349-354
pubmed: 31710400
Arch Ophthalmol. 1985 Dec;103(12):1796-806
pubmed: 2866759
JAMA Ophthalmol. 2020 Dec 1;138(12):1264-1271
pubmed: 33090189
PLoS One. 2016 Oct 7;11(10):e0164095
pubmed: 27716837
Proc Math Phys Eng Sci. 2021 Dec;477(2256):20210549
pubmed: 35153605
Curr Med Res Opin. 2022 Jun;38(6):955-962
pubmed: 35475495
Neurology. 2021 Jul 13;97(2):68-79
pubmed: 33910937
Lancet Neurol. 2010 Sep;9(9):921-32
pubmed: 20723847
J Neurol Sci. 2021 Jan 15;420:117213
pubmed: 33271374
Alzheimer Dis Assoc Disord. 1997;11 Suppl 5:S6-9
pubmed: 9348422
Emerg Themes Epidemiol. 2016 Oct 28;13:11
pubmed: 27800007
Nat Rev Neurol. 2022 Apr;18(4):203-220
pubmed: 35177849
Stat Methods Med Res. 2007 Jun;16(3):219-42
pubmed: 17621469
Brain. 2012 Feb;135(Pt 2):534-41
pubmed: 22300877
Ann Neurol. 2014 Jun;75(6):964-6
pubmed: 24816946
Public Health. 2017 May;146:4-9
pubmed: 28404473
Stat Med. 2009 Sep 30;28(22):2785-800
pubmed: 19591117
Clin Exp Optom. 2017 May;100(3):260-269
pubmed: 28295595
Invest Ophthalmol Vis Sci. 1990 Nov;31(11):2473-5
pubmed: 2243012
J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):419-24
pubmed: 24973342
BMJ Open. 2022 Mar 16;12(3):e058552
pubmed: 35296488
Mov Disord. 2021 May;36(5):1191-1202
pubmed: 33421201
J Neurol. 2021 Dec;268(12):4646-4654
pubmed: 33174132
Neurology. 2015 Mar 17;84(11):1104-13
pubmed: 25681454
Doc Ophthalmol. 2004 Jan;108(1):17-40
pubmed: 15104164
Brain Commun. 2019;1(1):fcz006
pubmed: 31608325
Biometrics. 1946 Dec;2(6):110-4
pubmed: 20287815
Eur J Ophthalmol. 2014 Jan-Feb;24(1):114-9
pubmed: 23828323
J Neurosci. 2009 Mar 18;29(11):3365-73
pubmed: 19295143
Lancet Neurol. 2011 Sep;10(9):797-805
pubmed: 21802993
Neurology. 2016 Jun 14;86(24):2303-9
pubmed: 27225223
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
J Parkinsons Dis. 2021;11(4):1585-1596
pubmed: 34486987
Ophthalmology. 2020 Jan;127(1):62-71
pubmed: 31585827